Livzon Pharmaceutical Group Inc (1513.HK)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- CORRECTED-BRIEF-Livzon Pharmaceutical Unit's JV Livzon Biologics' Capital Will Be Boosted By 600 Mln Yuan (Feb 7)
- BRIEF-Livzon Pharmaceutical Group To Sell 51% Stake In Livzon Mab To Biologics Ltd
- BRIEF-Livzon Pharmaceutical Group Announces Proposed Cash Dividend Distribution & Share Issue
- BRIEF-Livzon Pharmaceutical Group Says Joincare To Sell 49 PCT Equity Interests In Livzon Mab
- REFILE-BRIEF-Livzon Pharmaceutical'ss Board Agrees Unit To Invest $30 Mln In Global Health Science Fund II